

# ● PRINTER RUSH ●

(PTO ASSISTANCE)

|                                |                              |                          |
|--------------------------------|------------------------------|--------------------------|
| Application : <u>09/763037</u> | Examiner : <u>Low</u>        | GAU : <u>1614</u>        |
| From: <u>he</u>                | Location: <u>IDC</u> FMF FDC | Date: <u>11/8/04</u>     |
| Tracking #: <u>0600 8084</u>   |                              | Week Date: <u>9/6/04</u> |

| DOC CODE                                 | DOC DATE | MISCELLANEOUS                                |
|--|----------|--|
| <input type="checkbox"/> 1449            | _____    | <input type="checkbox"/> Continuing Data     |
| <input type="checkbox"/> IDS             | _____    | <input type="checkbox"/> Foreign Priority    |
| <input type="checkbox"/> CLM             | _____    | <input type="checkbox"/> Document Legibility |
| <input type="checkbox"/> IIFW            | _____    | <input type="checkbox"/> Fees                |
| <input type="checkbox"/> SRFW            | _____    | <input type="checkbox"/> Other               |
| <input type="checkbox"/> DRW             | _____    |  |
| <input type="checkbox"/> OATH            | _____    |  |
| <input type="checkbox"/> 312             | _____    |  |
| <input checked="" type="checkbox"/> SPEC | _____    |  |

[RUSH] MESSAGE: In footnote reference "c" of Table 1 it refers to  
bolded data. Cannot distinguish between bolded and non-bolded data.  
Please advise.

Thank you.

[XRUSH] RESPONSE: As pointed out by Applicant during  
a telephone interview on Feb 2, 2005, the  
circled data is bolded.

In addition this would appear to be an issue for PROBLEM  
IMAG & the page(s) should be rescaned.

INITIALS: CM

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.  
 REV 10/04

cell

TABLE 1. AZT/3TC prophylaxis of cats starting 3 days before FIV inoculation

| AZT/3TC treatment <sup>a</sup> |              |             | FIV levels <sup>b</sup> |      |      |       |       |     |      |      |       |       | FIV antibodies <sup>b</sup> |      |       |       | CD4/CD8 ratio <sup>bc</sup> |  |  |  |
|--------------------------------|--------------|-------------|-------------------------|------|------|-------|-------|-----|------|------|-------|-------|-----------------------------|------|-------|-------|-----------------------------|--|--|--|
| Cat #                          | (kg/mg)      | FIV inocul. | Pre                     | 4 wk | 9 wk | 11 wk | 14 wk | Pre | 4 wk | 9 wk | 11 wk | 14 wk | Pre                         | 7 wk | 11 wk | 14 wk |                             |  |  |  |
| DH5                            | 75-34-10     | +           | -/-                     | -/-  | -/-  | -/-   | -/-   | -   | -    | -    | -     | -     | -                           | 3.30 | 2.86  | 2.62  | 2.38                        |  |  |  |
| 3GB                            | 75-34-10-0-5 | +           | -/-                     | -/-  | -/-  | -/-   | -/-   | -   | -    | -    | -     | -     | -                           | 1.56 | 1.37  | 1.37  | 1.47                        |  |  |  |
| RU2                            | 75-34-10     | +           | -/-                     | -/-  | -/-  | -/-   | -/-   | -   | -    | -    | -     | -     | -                           | 1.77 | 1.21  | 1.18  | 1.18                        |  |  |  |
| RU1                            | 75-34-10     | -           | -/-                     | -/-  | -/-  | -/-   | -/-   | -   | -    | -    | -     | -     | -                           | 2.37 | 1.62  | 1.62  | 1.47                        |  |  |  |
| NK4                            | -            | +           | -/-                     | +/-  | +/-  | +/-   | +/-   | -   | -    | +    | +     | +     | +                           | 1.82 | 1.55  | 0.96  | 0.91                        |  |  |  |
| NK6                            | -            | +           | -/-                     | -/-  | +/-  | +/-   | +/-   | -   | -    | +    | +     | +     | +                           | 1.61 | 0.92  | 0.46  | 0.45                        |  |  |  |
| IO1                            | -            | +           | -/-                     | +/-  | +/-  | +/-   | +/-   | -   | -    | +    | +     | +     | +                           | 3.40 | 1.73  | 1.24  | 1.23                        |  |  |  |
| IH5                            | -            | +           | -/-                     | -/-  | +/-  | +/-   | +/-   | -   | -    | +    | +     | +     | +                           | 4.40 | 1.34  | 0.60  | 0.61                        |  |  |  |

<sup>a</sup> The AZT/3TC treatment was started 3 days before FIV inoculation (-0.4 post-infection) at a dose of 75 mg/kg each and decreased to 34 mg/kg at 4 wk post-infection (pi) and then to 10 mg/kg at 5 wk pi. In one cat (#3GB), the AZT/3TC treatment was withdrawn at 6 wk pi and resumed at a low dose of 5 mg/kg at 7 wk pi. The changes in doses if each drug, including the amount (mg/kg) and time (wk pi), are shown.

<sup>b</sup> Samples before drug or placebo treatment (Pre) and those at various weeks post-infection (wk) were tested for FIV levels, FIV antibodies, and CD4/CD8 ratios. FIV levels were determined by virus isolation (VI), PCR for FIV provirus in PBMC, and RT-PCR for plasma viral RNA (vRNA). FIV antibodies were determined by immunoblot analysis. In general, RT-PCR for plasma viral RNA was less sensitive than PCR of FIV provirus in PBMC after amplification of infected cells by coculturing.

<sup>c</sup> Inverted CD4/CD8 ratios are bolded.